Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating

Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated coverage of Novavax Inc. (NASDAQ:NVAX) with a Sell rating and a $6 price target.

Novavax Inc. (NVAX): Among Unstoppable Stocks That Could Double Your Money

A closeup of a vial of the biotechnology company’s vaccines.

The firm acknowledged that vaccines are a “key cornerstone” to global health, and that Novavax Inc. (NASDAQ:NVAX) could contribute to the development of new and innovative vaccines through its innovative technologies.

However, the analyst also told investors in a research note that establishing a clear path to success for Novavax Inc. (NASDAQ:NVAX) is proving challenging due to several factors.

These include the company’s “overwhelming concentration” in respiratory vaccines, an area that is continually undergoing decline in vaccination rates with several entrenched players. In addition, healthcare policies are “in flux” and generally “not encouraging” towards vaccines, further supporting the Sell rating.

Novavax Inc. (NASDAQ:NVAX) is a biotechnology company that discovers, develops, and commercializes recombinant vaccines.

While we acknowledge the potential of NVAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.